Ask Warren

JONBUR Research · Initiation

You're reading an earlier report from Oct 18, 2026. See the latest report

Prestige BioPharma · 950210 · Biotech & Pharma

Prestige BioPharma: Tiny Revenue, Persistent Operating Losses and a Share Price Down 55.9% Over a Year

Why this report

Start of coverage: written when a reader opened this company and there was no report yet.

Prestige BioPharma (KOSPI, Biotech & Pharma) has a market value of about ₩341.9B, while filed FY 2025 revenue was only about ₩10.2M and the operating loss was about ₩48.0M. The shares closed at ₩5,690 on 2026-10-16, down 55.9% over one year and up 7.6% over three months.

Written Oct 18, 2026 · Data as of Oct 16, 2026 · 0 views

This is not financial advice. The report does not recommend buying or selling anything.

XfWATGr/in@

Thesis

The data shows a company still at an early commercial stage: revenue has appeared only recently and operating losses have continued every year since 2021. FY 2025 net income was positive at about ₩15.9M despite the operating loss, which suggests the profit came from items outside operations, though the data does not say which. The market value is very large relative to sales, so the price reflects expectations that the filings alone do not show. No valuation model estimate is available, and no recent news headlines are in the data. Foreign ownership is high at 63.5%, little changed from 63.7% sixty days ago. Retail investors were net buyers over 20 days while foreign and institutional investors were net sellers.

Business overview

Prestige BioPharma is a Biotech & Pharma company listed on KOSPI on 2021-02-05 and founded on 2015-07-13. It has 60,096,155 listed shares and a market capitalization of about ₩341.9B. Filed revenue was zero in 2021 and 2022, then ₩122K in 2023, ₩517K in 2024 and ₩10.2M in 2025. Recent filings include annual general meeting results, an auditor change application, independent director changes, an annual report for June 2026 (with an amendment), an amended major sales or supply contract notice, and changes in the largest shareholder's holdings.

Every earlier JONBUR Research report and update note on Prestige BioPharma, with Pro.

Unlock with Pro

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Filings and data used

Report history

  1. Oct 29, 2026Update noteBig price movePrestige BioPharma Shares Fall 21.4% in Five Trading Days on Heavy Volume
  2. Oct 18, 2026InitiationStart of coverage (reader request)Prestige BioPharma: Tiny Revenue, Persistent Operating Losses and a Share Price Down 55.9% Over a Year

Built only from jonbur's own data: prices and investor flows, filed financial statements and filings, and news headlines. Disclosed (filed) data is labelled as such. Written by AI and may contain mistakes.

This is not financial advice. The report does not recommend buying or selling anything.

Source: KRX statistical information